Carl Zeiss Meditec AG (AFX) - Total Assets
Based on the latest financial reports, Carl Zeiss Meditec AG (AFX) holds total assets worth €3.40 Billion EUR (≈ $3.98 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Carl Zeiss Meditec AG shareholders equity for net asset value and shareholders' equity analysis.
Carl Zeiss Meditec AG - Total Assets Trend (2014–2025)
This chart illustrates how Carl Zeiss Meditec AG's total assets have evolved over time, based on quarterly financial data.
Carl Zeiss Meditec AG - Asset Composition Analysis
Current Asset Composition (September 2025)
Carl Zeiss Meditec AG's total assets of €3.40 Billion consist of 37.4% current assets and 62.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0.8% |
| Accounts Receivable | €209.01 Million | 6.1% |
| Inventory | €496.98 Million | 14.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €662.87 Million | 19.5% |
| Goodwill | €969.74 Million | 28.5% |
Asset Composition Trend (2014–2025)
This chart illustrates how Carl Zeiss Meditec AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Carl Zeiss Meditec AG market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Carl Zeiss Meditec AG's current assets represent 37.4% of total assets in 2025, a decrease from 67.0% in 2014.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2025, down from 1.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 16.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 28.5% of total assets.
Carl Zeiss Meditec AG Competitors by Total Assets
Key competitors of Carl Zeiss Meditec AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alcon AG
SW:ALC
|
Switzerland | CHF31.53 Billion |
|
iRay Technology Co Ltd
SHG:688301
|
China | CN¥11.33 Billion |
|
Shenyang Xingqi Pharmaceutical Co Ltd
SHE:300573
|
China | CN¥2.42 Billion |
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
|
USA | $32.49 Million |
|
Jiangsu Nanfang Medical
SHG:603880
|
China | CN¥993.46 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
I.Ceram SA
PA:ALICR
|
France | €3.91 Million |
Carl Zeiss Meditec AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.34 | 2.12 | 4.34 |
| Quick Ratio | 1.43 | 1.18 | 3.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €728.13 Million | €639.09 Million | €995.17 Million |
Carl Zeiss Meditec AG - Advanced Valuation Insights
This section examines the relationship between Carl Zeiss Meditec AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.04 |
| Latest Market Cap to Assets Ratio | 0.66 |
| Asset Growth Rate (YoY) | 0.3% |
| Total Assets | €3.40 Billion |
| Market Capitalization | $2.23 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Carl Zeiss Meditec AG's assets below their book value (0.66x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Carl Zeiss Meditec AG's assets grew by 0.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Carl Zeiss Meditec AG (2014–2025)
The table below shows the annual total assets of Carl Zeiss Meditec AG from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | €3.40 Billion ≈ $3.98 Billion |
+0.30% |
| 2024-09-30 | €3.39 Billion ≈ $3.97 Billion |
+11.88% |
| 2023-09-30 | €3.03 Billion ≈ $3.55 Billion |
+7.44% |
| 2022-09-30 | €2.82 Billion ≈ $3.30 Billion |
+17.82% |
| 2021-09-30 | €2.40 Billion ≈ $2.80 Billion |
+19.01% |
| 2020-09-30 | €2.01 Billion ≈ $2.35 Billion |
-0.44% |
| 2019-09-30 | €2.02 Billion ≈ $2.36 Billion |
+21.66% |
| 2018-09-30 | €1.66 Billion ≈ $1.94 Billion |
+2.40% |
| 2017-09-30 | €1.62 Billion ≈ $1.90 Billion |
+30.08% |
| 2016-09-30 | €1.25 Billion ≈ $1.46 Billion |
+9.52% |
| 2015-09-30 | €1.14 Billion ≈ $1.33 Billion |
+9.64% |
| 2014-09-30 | €1.04 Billion ≈ $1.21 Billion |
-- |
About Carl Zeiss Meditec AG
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for ret… Read more